Reported topline data results in July from the multi-center, international ASPEN-06 Phase 2 clinical trial (NCT05002127) evaluating evorpacept in combination with HERCEPTIN® (trastuzumab), CYRAMZA® ...
Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare ...
Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...
In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $1.53 per share, reflecting an increase of 1430% compared to the same period last year.
and Eli Lilly’s anti-VEGF drug Cyramza (ramucirumab) – in advanced solid tumours. The pharma group licensed ex-China rights to tusamitamab ravtansine from Chinese biotech Innovent in 2017 ...
The list including Bristol-Myers Squibb’s cancer immunotherapy Opdivo (nivolumab), Eli Lilly’s Cyramza (ramucirumab), Eisai’s Lenvima (lenvatinib), Bayer’s Stivarga (regorafenib) ...
Nov. 7, 2024 — Researchers have developed an innovative technique to search for black hole light echoes. Their novel method, which will make it easier for the mass and the spin of black holes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback